A new therapeutic platform based on nanotechnology to promote T- and B-regulatory networks

Project Information

NANOBreg

Grant agreement ID: 704522

DOI

10.3030/704522

Project closed

EC signature date 6 April 2016

Start date 1 May 2016

End date 13 May 2018

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost

€ 158 121,60

EU contribution

€ 158 121,60

Coordinated by

FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Spain

Periodic Reporting for period 1 - NANOBreg (A new therapeutic platform based on nanotechnology to promote T- and B-regulatory networks)

Reporting period: 2016-05-01 to 2018-04-30

Summary of the context and overall objectives of the project

Autoimmune diseases are caused by an attack of the immune system against self-tissues, resulting in a loss of structural and/or functional integrity of the targeted tissue. There are more than 100 known autoimmune diseases, affecting approximately 100 million people (~75% women) in both Europe and North America. Autoimmune inflammation associated to the disease is normally induced by cognate interactions between antigen presenting cells (APCs) and autoantigen-specific lymphocytes. An ideal therapy for these disorders would be one capable of selectively blunting the autoimmune response (e.g. targeting autoreactive lymphocytes) without impairing the host immunity.
Recently, Santamaria and colleagues discovered that systemic delivery of nanoparticles (NPs) coated with Type-1 Diabetes (T1D)-relevant specific molecules (figure 1) triggers the generation and subsequent expansion of memory autoregulatory T cells (TR1), restoring normoglycemia in diabetic animals. This Project aims at dissecting the mechanistic underpinnings of the cellular network that drives the protection to T1D observed by this new therapeutic platform.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

To be able to study the cellular interactions and mechanisms proposed, we have generated a new panel of tools: new specific NPs interacting with the desired T and B lymphocytes, new tools to be able to detect them, as well as new mouse strains that will afford us to investigate the desired cell populations. Although we have encountered some challenges to generate these tools, specially the new specific NPs, they have all been successfully generated. Using these new tools as well as others previously generated in the host laboratory, we have been able to generate specific TR1 cells, the cell type responsible for the restoration of normoglycemia in T1D mice, the main focus of this study. Using a technique called RNA-sequencing, we have been able to characterize them much further than ever before, confirming some previous results and uncovering new, very interesting molecules that are specific to this population. New experiments to further characterize these cells are currently on course. A similar study with specific Breg cells (the other main target of this study) will be done soon to complete the study. Yet, to characterize the role of B cells in NP treatments we have used a relevant, B cell dependent autoimmune disease: pemphigus vulgaris. Using a mouse model for this disease we have been able to reduce the levels of auto-antibodies in serum of mice treated with our specific NPs, showing that TR1 cells generated by the inoculated NPs are able to regulate antibody producing B cells.
Finally, we have used a model of humanized mice to test our specific NP treatments on human lymphocytes obtained from T1D donnors. We have been able to detect an increase in regulatory B cells that correlates with the upregulation of TR1 cells.
These results will afford the host lab to better understand the intrinsic mechanisms of this new therapy based on coated NPs, therefore increasing the chances of generating better treatments for a wider array of autoimmune diseases. Once these results are completed with the final experiments that are now on course, at least one scientific paper will be published in a high impact, open-access journal.
This project and results have also been disclosed to the scientific public in one national and one international Congresses, and to the general public in several talks given at cultural centers, schools and a science museum.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The reporting period has been highly fruitful and creative, leading into novel insights of the cellular mechanisms underlying this new therapeutic platform. The results obtained have greatly increased our knowledge on the regulatory networks that drive the protection induced by our nanomedicines.
All the results obtained so far will be of great importance in the development of this new therapeutic platform. Understanding all the mechanisms that drive the protection observed with the nanomedicines will afford the lab to prepare better medicines and expand them to other auto-immune diseases. For example, the results showing that the used nanomedicines can reduce the levels of autoantibodies in a B cell dependent autoimmune disease, will help to expand the range of autoimmune diseases that our nanotherapy can target to all those mediated by B cell produced autoantibodies.
The clinical and market potential of the proposed therapy is enormouse. Our results will enhance the Intelectual Property (IP) portfolio, including patents issued in several countris, including the EU and the US.

pMHC-coated Iron Oxide Nanoparticles